Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Highlights

Acumen Pharmaceuticals reported Q3 2026 net loss of $25.4 million and confirmed topline results from its ALTITUDE-AD Phase 2 study of sabirnetug in early Alzheimer's disease are expected in November 2026. Cash, cash equivalents and marketable securities stood at $78.6 million as of September 30, 2026, down from $110.2 million at June 30, and are expected to fund operations only into early 2027. The 542-patient Phase 2 readout on the iADRS primary endpoint is the company's defining near-term catalyst, with an IND submission for its Enhanced Brain Delivery program targeted for mid-2027.

•6d ago

Acumen Pharmaceuticals to Present Preliminary Baseline Characteristics and Data on Care Experiences and Participation in Phase 2 ALTITUDE-AD Trial at the 19th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference

Acumen Pharmaceuticals will present three posters on its Phase 2 ALTITUDE-AD trial of sabirnetug (ACU193) at the 19th Annual CTAD conference in Boston, November 16-19, 2026. The presentations cover preliminary baseline characteristics of enrolled participants plus qualitative data on patient and care-partner experiences — not new efficacy or safety results. ALTITUDE-AD has enrolled 542 individuals with early Alzheimer's disease across the US, Canada, EU and UK, with topline results still expected in late 2026.

•10d ago

Acumen Pharmaceuticals to Report Third Quarter Financial Results on October 26, 2026

Acumen Pharmaceuticals (NASDAQ: ABOS) will report third quarter financial results on Monday, October 26, 2026, with a conference call and webcast at 8:00 a.m. ET. This is a scheduling notice with no financial results or business data included. Acumen's lead asset is sabirnetug (ACU193), currently in a Phase 2 trial (ALTITUDE-AD) for early symptomatic Alzheimer's disease.

•13d ago

Acumen Pharmaceuticals to Hold Virtual Investor Day on September 16, 2026

Acumen Pharmaceuticals (NASDAQ: ABOS) will host a virtual Investor Day on Wednesday, September 16, 2026 at 10:00 a.m. ET, with registration required in advance and a webcast archived for at least one year. Acumen is a clinical-stage biopharmaceutical company developing therapeutics targeting toxic soluble amyloid beta oligomers for Alzheimer's disease; its lead candidate is sabirnetug (ACU193), currently in the Phase 2 ALTITUDE-AD trial in early symptomatic patients. The release contains no new clinical or financial data, but the investor day is a likely venue for pipeline updates on sabirnetug and its subcutaneous formulation and JCR collaboration programs.

•1mo ago

Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences

Acumen Pharmaceuticals (NASDAQ: ABOS) announced management will participate in two upcoming investor conferences: a fireside chat at the Cantor Global Healthcare Conference on September 9, 2026 at 3:55 p.m. ET, and another at Citi's 2026 Biopharma Back to School Conference on September 10, 2026 at 8:40 a.m. ET. Live webcasts will be accessible under the Investors tab on the company's website and archived for 90 days. Acumen is a clinical-stage biopharmaceutical company advancing sabirnetug (ACU193), a monoclonal antibody targeting toxic soluble amyloid beta oligomers, in its Phase 2 ALTITUDE-AD trial in early symptomatic Alzheimer's disease; the release contained no new clinical or financial data.

•1mo ago

Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights

Acumen Pharmaceuticals reported a Q2 net loss of $32.7 million, or ($0.45) per share, narrowing from a $41.0 million loss in the prior-year quarter as R&D expenses decreased to $27.8 million. The company holds $110.2 million in cash and equivalents, which management expects will support clinical and operational activities into early 2027. Acumen reiterated that topline results from the Phase 2 ALTITUDE-AD study of sabirnetug are anticipated in late 2026, while the EBD program targets a mid-2027 IND filing.

•2mo ago

Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 12, 2026

Acumen Pharmaceuticals announced it will report its second quarter financial results on Wednesday, Aug. 12, 2026. The company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update. Acumen is a clinical-stage biopharmaceutical company developing sabirnetug (ACU193), a humanized monoclonal antibody targeting toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease.

•2mo ago

Acumen Pharmaceuticals to Participate in the Bank of America Securities 2026 Health Care Conference

Acumen Pharmaceuticals announced that management will participate in a fireside chat at the Bank of America Securities 2026 Health Care Conference on May 14, 2026. The live webcast is scheduled for 8:55 a.m. PT and will be accessible via the Investors section of the company's website, with an archive available for 90 days. Acumen is a clinical-stage biopharmaceutical company focused on Alzheimer's disease, currently advancing its lead candidate sabirnetug in a Phase 2 trial.

•5mo ago

Acumen Pharmaceuticals to Report First Quarter Financial Results on May 12, 2026

Acumen Pharmaceuticals scheduled its first quarter 2026 financial results release for Tuesday, May 12, 2026. The company will host a conference call and live audio webcast at 8:00 a.m. ET on that day to provide a business update. This is a standard earnings calendar announcement with no financial figures disclosed in advance.

•5mo ago